Auriga Reiterates Buy, $10 PT On Affymax
Posted on December 08, 2011 at 13:10 PM EST
In a note out today, Auriga reiterated a buy rating and $10 price target on biotech firm Affymax (Nasdaq: AFFY), implying significant upside from where the shares currently trade.“Yesterday, the Oncology Drug Advisory Committee (ODAC) panel voted 1...